Transporter Cocktail

Phase 2Small molecule

Transporter Cocktail is one of 27 small molecule programs targeting Non-Small Cell Lung Cancer. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Non-Small Cell Lung CancerActive, not recruiting

Advanced or Metastatic NSCLCRecruiting

Non-Small Cell Lung CancerPhase 2

Active, not recruiting

Advanced or Metastatic NSCLCPhase 2

Recruiting

Competition

Competitive Landscape

1639 competitors in Non-Small Cell Lung Cancer

#DrugCompanyPhaseTrials

Yervoy

Bristol-Myers Squibb

Preclinical

31 2

Gemzar

GGynecologic Oncology Group

Preclinical

72 3

Lenvima

Eisai

Preclinical

6 4

Gilotrif

Boehringer Ingelheim

Preclinical

12 5

Ofev

Boehringer Ingelheim

Preclinical

7 6

Transporter Cocktail

Taiho Oncology, Inc.

Phase 2

2 7

Tyrosine Kinase Inhibitor

Pfizer

Preclinical

2 8

REGN2810

Regeneron

Preclinical

1 9

Vidaza

Bristol-Myers Squibb

Preclinical

1 10

Vibramycin

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

Phase 2Recruiting

Advanced or Metastatic NSCLC

NCT05967689

Clinical

Trials by Indication[1]

Interaction1 trial

Drug-Drug Interaction Study of MLC1501 Using Cocktail of Drugs Acting as Sensitive Clinical Probes/Substrates of Cytochrome P450 Isoenzymes and Transporters in Healthy Subjects

Completed·MMoleac Pte Ltd.·Phase 1·NCT04233437·27 enrolled

Advanced or Metastatic NSCLC1 trial

An Open-Label, Phase 2b, Global Multicenter Cohort Trial to Assess the Safety and Efficacy of Zipalertinib in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer With Exon 20 Insertion and Uncommon/Single or Compound Epidermal Growth Factor Receptor Mutations.

Recruiting· Taiho Oncology, Inc. logo

Taiho Oncology, Inc.·Phase 2·NCT05967689·220 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Transporter Cocktail. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Transporter Cocktail compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Transporter Cocktail. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Taiho Oncology, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Taiho Oncology, Inc.

Transporter Cocktail

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2028

Trials by Indication[1]

Interaction1 trial

Advanced or Metastatic NSCLC1 trial

References

Drug Info

Quick Facts

Related News